The EUROPA Trial:Can an ACE Inhibitor Reduce CV Events in Stable CAD Patients Across the Risk Spectrum?1,2
…Even in patients ≤ 55 years of age
Landmark ACE inhibitor CAD outcomes study in 12,218 patients 1,2
Multicenter, randomized, double-blind, placebo-controlled study 1,2
Studied a broad population of stable CAD patients without clinical heart failure, similar to those seen in daily practice (see table) 1,2
Approximately one-third of patients in the study were aged 55 years or less 1,2
Majority of patients were also receiving contemporary CV protective therapies 1,2
Selected inclusion criteria and patient demographics of the EUROPA trial1,2
The EUROPA placebo event rate reflects a broad risk spectrum of stable CAD patients including those also receiving contemporary CV protective therapies. 1,2
